Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07486869 Emapalumab-LZSG Amyopathic Dermatomyositis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07486869 clinical trial report covering Emapalumab-LZSG, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07487805 Ivermectin Solid tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07487805 clinical trial report covering Ivermectin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261131 AAPB Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
CTR20261131 clinical trial report covering AAPB, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600121031 Cadonilimab Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600121031 clinical trial report covering Cadonilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07489534 PD-1Ab21-BCMA CAR-T(Chinese People's Liberation Army General Hospital) Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07489534 clinical trial report covering PD-1Ab21-BCMA CAR-T(Chinese People's Liberation Army General Hospital), Phase 2, endpoints, sponsor, geography,
Latest Hotspot
8 min read
NCT07491458 HU-6 Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07491458 clinical trial report covering HU-6, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07489989 Chidamide Diffuse large B-cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07489989 clinical trial report covering Chidamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07489209 EDP167 Homozygous familial hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07489209 clinical trial report covering EDP167, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600121010 Cetuximab Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600121010 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07491783 Carbon Nanoparticles Soft Tissue Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07491783 clinical trial report covering Carbon Nanoparticles, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07489300 Anlotinib Dihydrochloride Platinum-Resistant Primary Peritoneal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07489300 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07489703 Trastuzumab Rezetecan Locally Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07489703 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.